Treace Medical's Revenue Fell 4%. It Raised Guidance Anyway, on Bunion Surgery Volume

Treace Medical Concepts, which makes surgical systems used in bunion-correction procedures, reported second-quarter 2026 revenue of $45.4 million, down 4% from a year earlier. On its own, a revenue decline usually pressures a stock — but Treace moved the other way, rising as much as 6.98% on the day, because of what the company did with its full-year outlook.

Treace raised its full-year 2026 revenue guidance to a range of $204 million-$212 million, up from a prior range of $202 million-$212 million. The raise is modest at the low end and unchanged at the high end, but the range itself — implying anywhere from a 4% full-year revenue decline to flat versus 2025 — reads as more confident than the Q2 revenue decline alone would suggest. The company also narrowed its expected full-year adjusted EBITDA loss to $3.0 million-$5.0 million, from a prior expected loss of $4.0 million-$6.0 million, meaning it now expects to lose less money on an adjusted basis than it previously projected.

Management tied the improved outlook to rising bunion-correction case volumes, greater adoption of the company's newer bunion surgical systems among surgeons, and market share gains — in other words, the argument is that the underlying surgical-procedure business is strengthening even though the specific quarter that just closed showed a revenue decline, which is why the guidance raise carried more weight with the market than the trailing quarter's number did.